Tech Company Financing Transactions

Pearl Therapeutics Funding Round

On 7/3/2008, Pearl Therapeutics raised $18 million in Series A funding from 5AM Ventures, Clarus and New Leaf Venture Partners.

Transaction Overview

Company Name
Announced On
7/3/2008
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Series A
Investors

5AM Ventures

Clarus (Nicholas Simon)

New Leaf Venture Partners (Kathleen LaPorte)

Proceeds Purpose
This additional capital will allow us to broaden and progress development efforts on our products and delivery platform," said Adrian Smith, President, and co-founder of Pearl.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Saginaw Drive
Redwood City, CA 94063
USA
Email Address
Overview
Pearl Therapeutics is focused on developing a pipeline of novel andsuperior products for chronic respiratory disorders, providing patientswith advanced therapeutic options in familiar and well accepted dosageforms. The company has licensed advanced particle technology from NektarTherapeutics (Nasdaq: NKTR) for developing a series of products in selectedtherapeutic fields.
Profile
Pearl Therapeutics LinkedIn Company Profile
Social Media
Pearl Therapeutics Company Twitter Account
Company News
Pearl Therapeutics News
Facebook
Pearl Therapeutics on Facebook
YouTube
Pearl Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Charles Bramlage
  Charles Bramlage LinkedIn Profile  Charles Bramlage Twitter Account  Charles Bramlage News  Charles Bramlage on Facebook
Chief Medical Officer
Colin Reisner
  Colin Reisner LinkedIn Profile  Colin Reisner Twitter Account  Colin Reisner News  Colin Reisner on Facebook
Chief Scientific Officer
Sarvajna Dwivedi
  Sarvajna Dwivedi LinkedIn Profile  Sarvajna Dwivedi Twitter Account  Sarvajna Dwivedi News  Sarvajna Dwivedi on Facebook
VP - Bus. Development
Lyn Baranowski
  Lyn Baranowski LinkedIn Profile  Lyn Baranowski Twitter Account  Lyn Baranowski News  Lyn Baranowski on Facebook
VP - Finance
William Picht
  William Picht LinkedIn Profile  William Picht Twitter Account  William Picht News  William Picht on Facebook
VP - Product Management
Robert Schultz
  Robert Schultz LinkedIn Profile  Robert Schultz Twitter Account  Robert Schultz News  Robert Schultz on Facebook
VP - Regulatory Affairs
Michael Golden
  Michael Golden LinkedIn Profile  Michael Golden Twitter Account  Michael Golden News  Michael Golden on Facebook


 

 

Browse more venture capital transactions:

Prev: 7/2/2008: Oversight Systems venture capital transaction
Next: 7/3/2008: Core Essence Orthopaedics venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary